UPMC Study Reveals Opioids' Negative Impact on Cancer Immunotherapy
TL;DR
Glycyx advances axelopran to address opioid-induced immunotherapy failure, gaining IND status for clinical trials.
Axelopran, a mu-opioid receptor antagonist, targets immunosuppression to enhance immune checkpoint inhibitors for cancer treatment.
Glycyx's research on opioid effects in cancer treatment aims to improve outcomes, supporting better immunotherapy options for patients.
Publication in JITC highlights critical findings on opioids and immunotherapy, paving the way for innovative cancer treatment strategies.
Found this article helpful?
Share it with your network and spread the knowledge!
A groundbreaking study published in the Journal for ImmunoTherapy of Cancer has revealed the detrimental effects of opioids on cancer immunotherapy, potentially transforming approaches to pain management in cancer care. The research, conducted by a team at the University of Pittsburgh and UPMC Hillman Cancer Center, demonstrates how opioids impair the efficacy of immune checkpoint inhibitors (ICIs), a crucial class of cancer treatments.
Led by Dr. Nicole N. Scheff, the study provides critical insights into the mechanisms of opioid-induced immunotherapy failure (OIIF). This phenomenon could explain why some cancer patients fail to respond to immunotherapy, a treatment that has revolutionized cancer care in recent years. The findings suggest that commonly prescribed opioids for pain management may inadvertently compromise the very treatments designed to combat cancer.
The implications of this research are far-reaching. For oncologists and patients alike, it raises important questions about the balance between pain management and treatment efficacy. The study underscores the urgent need for alternative pain management strategies that do not interfere with cancer treatments.
In response to these findings, biopharmaceutical company Glycyx is advancing axelopran, a novel opioid antagonist designed to block the immunosuppressive effects of opioids while preserving their pain-relieving properties. With an active Investigational New Drug (IND) application with the FDA, Glycyx is poised to begin human clinical trials, potentially offering a solution to the OIIF problem.
The development of axelopran represents a significant step forward in addressing the challenges highlighted by the UPMC study. If successful, it could allow cancer patients to receive necessary pain relief without compromising their immunotherapy treatment. This approach could potentially improve treatment outcomes and quality of life for countless cancer patients worldwide.
As the field of oncology continues to evolve, the intersection of pain management and immunotherapy efficacy is likely to become an increasingly important area of focus. The UPMC study and Glycyx's development of axelopran highlight the critical need for interdisciplinary approaches in cancer research and treatment, bringing together experts in neurobiology, oncology, and pharmacology to address complex challenges in patient care.
Curated from Reportable
